MedTrace Logo

A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

NCT03710915 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-10-10

No results posted yet for this study

Summary

This study is designed to evaluate the tolerability and safety of HG146 capsule in patients with multiple myeloma.

Conditions

Interventions

DRUG

HG146

HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.

Sponsors & Collaborators

  • HitGen Inc.

    lead INDUSTRY

Principal Investigators

  • Ting Liu, M.D. · The West China Hospital of Sichuan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-12
Primary Completion
2022-09-28
Completion
2023-06-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03710915 on ClinicalTrials.gov